Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Phase 3

Active, not recruiting

• Conditions: Breast Cancer Stage IV
• Interventions: Drug: Camrelizumab+Apatinib+Eribulin; Drug: Physician's choice chemotherapy

• Registration Number: NCT06889688
• Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Brief Summary

This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity.

Detailed Description

This study aims to evaluate the efficacy and safety of the triplet regimen compared to physician's choice chemotherapy as a later-line treatment for advanced triple-negative breast cancer (TNBC). 1. Primary Objectives and Endpoints: To determine whether the combination of camrelizumab, apatinib, and eribulin improves progression-free survival (PFS) and overall survival (OS) compared to investigator's choice chemotherapy in advanced TNBC. 2. Secondary Objectives and Endpoints: To compare the following clinical parameters between the camrelizumab, apatinib, and eribulin combination and investigator's choice chemotherapy for advanced TNBC: -Objective response rate (ORR) Disease control rate (DCR) Clinical benefit rate (CBR) Duration of response (DoR) Time to response (TTR) Two-year overall survival rate (2-year OS rate) Biomarker analysis Quality of life (QoL) analysis 3.Safety Evaluation: Comparison of the incidence and severity of adverse events between the two groups.

Study Timeline

• Study First Submitted: 2025-03-11
• Study First Submitted QC: 2025-03-19
• Study First Posted: 2025-03-21
• Study Start: 2025-04-01
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-13
• Last Update Posted: 2025-05-15
• Primary Completion: 2030-09-20
• Study Completion: 2031-03-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Female
• Target Recruitment: 246

Inclusion Criteria

1. The subject voluntarily agrees to participate in this study and signs an informed consent form (ICF).
2. Female subjects aged ≥18 and ≤70 years on the date of signing the ICF.
3. Pathologically confirmed advanced triple-negative breast cancer (TNBC), defined as ER-negative (IHC ER-positive percentage <1%), PR-negative (IHC PR-positive percentage <1%), and HER2-negative (IHC-/+, or IHC++ but FISH/CISH-), with at least one measurable lesion per RECIST v1.1 criteria.
4. Previously received ≥1 line of systemic therapy for metastatic or locally advanced unresectable TNBC with disease progression. Prior systemic therapy (including ≥1 line of chemotherapy and neoadjuvant/adjuvant chemotherapy) must have included a taxane or anthracycline. Recurrence within 6 months after completing neoadjuvant/adjuvant chemotherapy is considered as failure of first-line therapy.
5. Capable of swallowing tablets.
6. ECOG performance status of 0-1.
7. Expected survival ≥12 weeks.
8. Adequate function of vital organs, meeting the following criteria (without the use of blood products or growth factors during the screening period): Absolute neutrophil count (ANC) ≥1.5×10⁹/L. Platelet count ≥100×10⁹/L. Hemoglobin ≥9 g/dL. Serum albumin ≥3 g/dL. Thyroid-stimulating hormone (TSH) ≤ULN (if abnormal, T3 and T4 levels should be assessed; subjects with normal T3 and T4 levels are eligible). Total bilirubin ≤1.0×ULN (for subjects with Gilbert's syndrome or liver metastases, total bilirubin ≤1.5×ULN). ALT and AST ≤1.5×ULN (for subjects with liver metastases, ≤3×ULN). Alkaline phosphatase (ALP) ≤2.5×ULN. Renal function within 7 days prior to the first dose: serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min.
9. Women of childbearing potential agree to use highly effective contraception starting at least 7 days prior to the first dose and continuing for 24 weeks after the last dose. A negative serum pregnancy test is required within 7 days prior to the first dose.

Exclusion Criteria

1. Subjects with untreated active brain metastases or leptomeningeal metastases.
2. Participation in any other interventional clinical trial within 28 days prior to the first dose.
3. History of severe allergic reactions to other monoclonal antibodies.
4. Receipt of other antitumor therapies within 28 days prior to the first dose.
5. Uncontrolled hypertension despite antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg).
6. Prior treatment with CTLA-4, Tim-3, or LAG-3 antibodies, or T-cell co-stimulatory therapies (previous use of PD-1 or PD-L1 antibodies is allowed).
7. Prior treatment with anti-angiogenic agents or eribulin chemotherapy.
8. Presence of any active autoimmune disease or a history of autoimmune disease (including but not limited to autoimmune hepatitis, interstitial pneumonitis, uveitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism). Subjects with vitiligo, or childhood asthma that has fully resolved without intervention in adulthood, may be included. Subjects with asthma requiring medical intervention with bronchodilators are excluded.
9. Uncontrolled cardiac clinical symptoms or diseases, including: Heart failure classified as NYHA Class II or higher. Unstable angina. Myocardial infarction within the past year. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.
10. Urinalysis indicating proteinuria ≥++ or confirmed 24-hour urinary protein ≥1.0 g.
11. Known hereditary or acquired bleeding or thrombotic disorders (e.g., hemophilia, coagulopathy, thrombocytopenia, hypersplenism).
12. Congenital or acquired immunodeficiency (e.g., HIV infection).
13. Receipt of a live vaccine within 4 weeks prior to or during the study period.
14. Allergy or contraindication to the investigational drugs.
15. Underwent surgery within 3 months prior to enrollment or anticipated need for major surgical procedures during the study period.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental Group	Camrelizumab+Apatinib+Eribulin	Camrelizumab (200 mg, IV, Day 1) + Apatinib (250 mg, PO, QD) + Eribulin (1.4 mg/m², IV, Day 1 and Day 8) administered in 21-day cycles.
Control Group	Physician's choice chemotherapy	Physician's Choice Chemotherapy

Primary Outcome Measures

Name	Time	Method
Progression-Free Survival	Time from enrollment to the occurrence of predefined events, including disease progression or death, whichever came first, assessed up to 60 months.	Disease evaluation will be performed according to RECIST v1.1 criteria.
Overall Survival	From date of randomization until the date of death from any cause, assessed up to 120 months.	Death from any cause.

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate	From date of randomization until the date of first documented CR or PR, whichever came first, assessed up to 12 months.	The percentage of patients in different groups whose tumor size reduction, meets the criteria for complete response (CR) or partial response (PR).
Disease control rate	From date of randomization until the date of first documented CR, PR or SD, assessed up to 12 months.	Proportion of patients achieving CR, PR, or stable disease (SD).
Clinical Benefit Rate	From date of randomization until the date of first documented CR, PR or SD for more than 6month, assessed up to 18 months.	Proportion of patients achieving CR, PR, or SD.
Duration of Response	Time from the first assessment showing CR or PR to the first occurrence of PD or death from any cause, whichever came first, assessed up to 120 months.	Time from the first assessment showing CR or PR to the first occurrence of progressive disease (PD) or death from any cause.
Time to Response	Time from randomization to the first occurrence of CR or PR, whichever came first, assessed up to 6 months	Time from randomization to the first occurrence of CR or PR.
Two-Year Overall Survival Rate	Two years after randomization.	Proportion of patients alive two years after randomization.
Safety Evaluation	From randomization to 30 days after the last dose of study treatment.	Comparison of the incidence and severity of adverse events between the two groups.

Trial Locations

Locations (6)

Sun Yat-sen Memorial Hospital; 🇨🇳 Guangzhou, Guangdong, China

The Affiliated Hospital of Guizhou Medical University; 🇨🇳 Guiyang, Guizhou, China

Wuhan Union Hospital of China; 🇨🇳 Wuhan, Hubei, China

Yichang Central People's Hospital; 🇨🇳 Yichang, Hubei, China

Xiangya Hospital of Central South University; 🇨🇳 Changsha, Hunan, China

The Central Hospital Of Yong Zhou; 🇨🇳 Yongzhou, Hunan, China